CTAK Surgery for Keratoconus

(CTAK Trial)

Overseen By Edward Manche, MD

Age: 18+

Sex: Any

Trial Phase: Phase 4

Sponsor: Stanford University

Disqualifiers: Thin cornea, Corneal scarring

No Placebo Group All trial participants will receive the active study treatment (no placebo)

Prior Safety Data This treatment has passed at least one previous human trial

Compensation: Varies

Number of Visits: 1

Duration: 1 day

What You Need to Know Before You Apply

What is the purpose of this trial?

Measuring quality of vision and quality of life outcomes using a validated questionnaire in participants undergoing CTAK surgery for corneal ectasia

Are You a Good Fit for This Trial?

Inclusion Criteria

I have corneal ectasia or keratoconus.

Exclusion Criteria

My corneas are too thin.

I have significant scarring on my cornea.

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants undergo CTAK surgery for corneal ectasia

1 day

1 visit (in-person)

Follow-up

Participants complete preoperative and postoperative questionnaires to measure quality of vision and quality of life

1 year

Multiple visits (in-person and virtual)

What Are the Treatments Tested in This Trial?

Interventions

• CTAK Surgery

How Is the Trial Designed?

Group I: Patient reported outcomes after CTAK surgery Experimental Treatment 1 Intervention

All subjects will complete preoperative and postoperative questionnaires

Who Is Running the Clinical Trial?

Stanford University

Lead Sponsor

Trials

2,527

Recruited

17,430,000+